Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature

Overview

Journal Am J Clin Dermatol

Specialty Dermatology

Date 2022 Apr 16

PMID 35428934

Authors

Mika Yamanaka-Takaichi

Soha Ghanian

David A Katzka

Rochelle R Torgerson

Afsaneh Alavi

Affiliations

Soon will be listed here.

Abstract

Anti-interleukin (IL)-17 agents have shown excellent therapeutic efficacy in patients with psoriasis and are expected to be expanded to other chronic inflammatory diseases. However, patients receiving anti-IL-17 agents are at an increased risk of developing Candida infection, with some agents reported to increase the incidence in a dose-dependent manner. Interleukin-17 is secreted by the Th17 subset of CD4+ lymphocytes, CD8+ T cells, and innate cells, including natural killer T cells, lymphoid tissue inducer cells, innate lymphoid cells, and γδ-T cells, and plays an important role in antifungal defense. Genetic defects in the IL-17-signaling pathway in both humans and animal models render susceptibility to candidiasis caused by Candida albicans. The purpose of this narrative review is to evaluate the literature on the role of IL-17 in protection against candidiasis, the prevalence of candidiasis in anti-IL-17 agent use, and to offer clinical recommendations on the diagnosis and management of anti-IL-17 medication-associated candidiasis.

Citing Articles

Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa.

Pinto Salgueiro G, Yilmaz O, Nogueira M, Torres T BioDrugs. 2024; 39(1):53-74.

PMID: 39604776 PMC: 11750882. DOI: 10.1007/s40259-024-00687-w.

Gene expression profiling reveals host defense strategies for restricting invasion and gastritis to the limiting ridge of the murine stomach.

Zeise K, Falkowski N, Metcalf J, Brown C, Huffnagle G Infect Immun. 2024; 92(12):e0043824.

PMID: 39535200 PMC: 11629626. DOI: 10.1128/iai.00438-24.

Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi.

Wang Z, Shao J Arch Microbiol. 2024; 206(7):293.

PMID: 38850421 DOI: 10.1007/s00203-024-04010-7.

Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management.

Bilal H, Khan M, Khan S, Fang W, Chang W, Yin B Mycology. 2024; 15(1):30-44.

PMID: 38558839 PMC: 10977001. DOI: 10.1080/21501203.2023.2265664.

Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.

Wu S, Xu Y, Yang L, Guo L, Jiang X Front Immunol. 2023; 14:1294416.

PMID: 38106423 PMC: 10721978. DOI: 10.3389/fimmu.2023.1294416.

References

Dongari-Bagtzoglou A, Fidel Jr P . The host cytokine responses and protective immunity in oropharyngeal candidiasis. J Dent Res. 2005; 84(11):966-77. DOI: 10.1177/154405910508401101. View

Armstrong A, Bukhalo M, Blauvelt A . A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis. Am J Clin Dermatol. 2016; 17(4):329-36. PMC: 4963441. DOI: 10.1007/s40257-016-0206-4. View

Hoversten P, Otaki F, Katzka D . Course of Esophageal Candidiasis and Outcomes of Patients at a Single Center. Clin Gastroenterol Hepatol. 2018; 17(1):200-202.e1. DOI: 10.1016/j.cgh.2018.04.035. View

Akpan A, Morgan R . Oral candidiasis. Postgrad Med J. 2002; 78(922):455-9. PMC: 1742467. DOI: 10.1136/pmj.78.922.455. View

Picciani B, Michalski-Santos B, Carneiro S, Sampaio A, Regazzi Avelleira J, Azulay D . Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. J Am Acad Dermatol. 2013; 68(6):986-91. DOI: 10.1016/j.jaad.2012.11.033. View

He C, Xue C, Zhu G, Kang P . Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta-analysis. J Clin Pharm Ther. 2021; 46(4):895-906. DOI: 10.1111/jcpt.13416. View

Ritchlin C, Krueger J . New therapies for psoriasis and psoriatic arthritis. Curr Opin Rheumatol. 2016; 28(3):204-10. PMC: 5812682. DOI: 10.1097/BOR.0000000000000274. View

Reich K, Warren R, Lebwohl M, Gooderham M, Strober B, Langley R . Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med. 2021; 385(2):142-152. DOI: 10.1056/NEJMoa2102383. View

Conti H, Shen F, Nayyar N, Stocum E, Sun J, Lindemann M . Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009; 206(2):299-311. PMC: 2646568. DOI: 10.1084/jem.20081463. View

10.

Saunte D, Mrowietz U, Puig L, Zachariae C . Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2016; 177(1):47-62. DOI: 10.1111/bjd.15015. View

11.

Fidel Jr P . Candida-host interactions in HIV disease: implications for oropharyngeal candidiasis. Adv Dent Res. 2011; 23(1):45-9. PMC: 3144040. DOI: 10.1177/0022034511399284. View

12.

Langley R, Elewski B, Lebwohl M, Reich K, Griffiths C, Papp K . Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014; 371(4):326-38. DOI: 10.1056/NEJMoa1314258. View

13.

Mrowietz U, Leonardi C, Girolomoni G, Toth D, Morita A, Balki S . Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015; 73(1):27-36.e1. DOI: 10.1016/j.jaad.2015.04.011. View

14.

Thaci D, Humeniuk J, Frambach Y, Bissonnette R, Goodman J, Shevade S . Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015; 173(3):777-87. DOI: 10.1111/bjd.13814. View

15.

Blauvelt A, Prinz J, Gottlieb A, Kingo K, Sofen H, Ruer-Mulard M . Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2014; 172(2):484-93. DOI: 10.1111/bjd.13348. View

16.

Mease P, McInnes I, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D . Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015; 373(14):1329-39. DOI: 10.1056/NEJMoa1412679. View

17.

McInnes I, Mease P, Kirkham B, Kavanaugh A, Ritchlin C, Rahman P . Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386(9999):1137-46. DOI: 10.1016/S0140-6736(15)61134-5. View

18.

Papp K, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C . A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016; 175(2):273-86. DOI: 10.1111/bjd.14493. View

19.

Papp K, Leonardi C, Menter A, Thompson E, Milmont C, Kricorian G . Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014; 71(6):1183-1190.e3. DOI: 10.1016/j.jaad.2014.08.039. View

20.

Yamasaki K, Nakagawa H, Kubo Y, Ootaki K . Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2016; 176(3):741-751. DOI: 10.1111/bjd.14702. View